Rani Therapeutics Director Jean‑Luc Butel Receives 123,600‑Share Award

What Happened Jean‑Luc Butel, a director of Rani Therapeutics Holdings, Inc. (RANI), was granted a derivative award on 2026-05-28 covering 123,600 shares. The filing reports the acquisition price as $0 (derivative). This is a grant/award of equity (not a sale or open‑market purchase) and does not represent an immediate sale of shares.

Key Details

• Transaction type/date: Grant/award (derivative) on 2026-05-28; Form 4 filed 2026-06-01 (timely).
• Quantity and price: 123,600 shares acquired as a derivative instrument at $0.00 per share (reported value $0).
• Vesting: Per footnote, the shares subject to the option vest in full on the first anniversary of the grant, subject to continuous service; they may vest earlier upon the company’s next annual meeting or a Change in Control, subject to service.
• Shares owned after transaction: Not specified in this Form 4.
• Filing status: Timely filed (within the two business‑day reporting window).

Context This filing documents an equity award (option/derivative), not an exercised option or sale. Such grants are common for directors and are typically subject to service and vesting conditions; they do not necessarily indicate immediate buying or selling intent.